

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SYS6017 (HERPES ZOSTER mRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYS6017 (herpes zoster mRNA vaccine) (the “**Product**”) developed by the Group has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product comprises mRNA molecules encoding the glycoprotein E (gE) of the varicella-zoster virus (VZV) encapsulated in a lipid nano-particle and is designed to prevent herpes zoster infections. Preclinical studies demonstrated that the Product could effectively induce humoral and cellular immune responses. Safety evaluation data also indicated that the Product had good safety profile, with the potential to exhibit a lower incidence of adverse reactions in clinical trials.

The global incidence rate of herpes zoster in the general population is 3–5 cases per 1,000 person-years. With increasing age, the proliferative capacity of VZV-specific T cells declines and cellular immunity weakens. VZVs which have been lying dormant in the nerves for a long time are more easily reactivated. Therefore, the incidence rate of herpes zoster increases with age: 6–8 cases per 1,000 person-years at age 60 and 8–12 cases per 1,000 person-years at age 80. In recent years, there has been a trend of herpes zoster occurring at younger ages, especially in sub-healthy individuals and immunocompromised groups such as patients with tumors and HIV, facing a significantly higher risk of developing herpes zoster. Currently, no mRNA vaccines targeting VZV infections are available on the market globally. The Group is committed to advancing the clinical research of the Product, striving to bring the Product to market as early as possible.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 7 February 2025

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.